The maker of Claude wants AI labs, including itself, to prepare for a coordinated slowdown if models begin building their own ...

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Recursion (RXRX). The reason why I want to go over this biotech next is because the company ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Elon Musk's social network X (formerly known as Twitter) last night released some of the code and architecture of its overhauled social recommendation algorithm under a permissive, enterprise-friendly ...

It’s hard to ignore the seismic shifts brought about by algorithm-driven content. Every time you scroll through your social media feed or check your favorite news app, algorithms are diligently at ...

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

A2Z/ ├── Problems/ # Solved problems organized by difficulty │ ├── Easy/ # Easy level problems │ ├── Medium/ # Medium level problems │ └── Hard/ # Hard level problems │ ├── DataStructures/ # Core data ...

Hi, everyone, and welcome. I'm Najat Khan, Recursion's Chief R&D and Chief Commercial Officer and incoming CEO and President. Let's jump right in. Today is an important moment for Recursion, for our ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...